

Prestige Brands

NYSE - PBH

Who We Are and Review of Second Quarter FY 17 Results

Morgan Stanley Leveraged Finance Conference
New Orleans, November 10, 2016



Safe Harbor Disclosure

This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenue growth, adjusted EPS, and adjusted free cash flow, expansion of market share for the Company’s Invest for Growth brands, the Company’s investment in digital, product development and marketing initiatives, the impact of and expected use of proceeds from recent brand divestitures, and the Company’s ability to de-lever and increase M&A capacity. Words such as “continue,” “will,” “expect,” “project,” “anticipate,” “likely,” “estimate,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, general economic and business conditions, regulatory matters, competitive pressures, the impact of the Company’s digital, product development and marketing initiatives, supplier issues, unexpected costs, and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2016. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are reconciled to their closest GAAP measurement in the attached reconciliation schedule and in our earnings release in the “About Non-GAAP Financial Measures” section.

Agenda for Today's Discussion

I. Who Is Prestige Brands?

II. Performance Highlights

III. Financial Overview

IV. FY 17 Outlook and the Road Ahead

I. Who Is Prestige Brands?

Dramamine®

Compound W[®]
WART REMOVER

DenTek®

LUDEN'S®

eat the foods you love!
beano®

LITTLE
REMEDIES®

Efferdent®
ANTI-BACTERIAL DENTURE CLEANSER

Clear
eyes®

BC®

Goody's®

FAST ACTING
Chloraseptic®

Nix®
PERMETHRIN

Hydralyte™

MONISTAT®

Gaviscon
and it's gone®

Debrox®

Care™
Pharmaceuticals

Prestige Brands is the largest independent OTC products Company in North America.

The Company markets and sells well-known, brand name over-the-counter healthcare and household cleaning products throughout the U.S. and Canada, Australia, and certain other international markets. We operate in niche segments within these categories in which the strength of our brand names, our established retail distribution network, a low cost operating model and experienced management team are key to our success.

3 Key Drivers of Long-Term Shareholder Value

Grow Our Invest for Growth Portfolio

- Portfolio of recognizable brands in attractive consumer health industry
- Established expertise in brand-building and product innovation
- Demonstrated ability to gain market share long-term
- Target revenue contribution from Core OTC and International brands from ~80% to ~85%


Deliver Industry-Leading and Consistent Free Cash Flow

- Strong and consistent cash flow driven by industry leading EBITDA margins, capital-lite business model & significant benefit of deferred taxes
- Rapid deleveraging allows for expanded acquisition capacity and continued investment in brand building
- Non-core brands' contribution to cash flow
- Debt repayment reduces cash interest expense and adds to EPS

Strategic and Disciplined M&A Strategy

- Demonstrated track record of 7 acquisitions during the past 6 years
- Effective consolidation platform positioned for consistent pipeline of opportunities
- Proven ability to source from varied sellers
- Fragmented industry and acquisition activity creates a consistent pipeline of opportunity

Diversified Portfolio of Leading, Trusted Brands



Source: Company filings for OTC revenues for FY 16
 Note: Pro forma for DenTek acquisition; excludes Household

Portfolio Composed of Brands with #1 / #2 Positions Across Key Segments Within Larger Categories

Gastrointestinal



Eye & Ear Care



Oral Care



Skin Care



Women's Health



Cough/Cold



Analgesics



72% of
Total OTC Sales

Source: Company information; illustrative set of #1 / #2 brands shown; reflects brand level gross sales for FY 16

Our Portfolio of Invest for Growth OTC Brands

"Power" Core \$100MM+ Brands

MONISTAT[®]

Clear
eyes.

BC

Goody's

DenTek

Core

Dramamine[®]

Nix
PERMETHRIN

Debrox[®]

FAST ACTING
Chloraseptic

LUDEN'S

LITTLE
REMEDIES

Compound W.
WART REMOVER

International

Care[™]
Pharmaceuticals

Hydralyte[™]

FESS

GAVISCON
and it's gone[®]
(Canada)

II. Performance Highlights

Dramamine®

Compound W[®]
WART REMOVER

DenTek[®]

LUDEN'S[®]

eat the foods you love!
beano[®]

LITTLE
REMEDIES[®]

Efferdent[®]
ANTI-BACTERIAL DENTURE CLEANSER

Clear
eyes[®]

BC[®]

Goody's[®]

FAST ACTING
Chloraseptic[®]

Nix[®]
PERMETHRIN

Hydralyte[™]

MONISTAT[®]

Gaviscon[®]
and it's gone[®]

Debrox[®]

Care[™]
Pharmaceuticals

Another Strong Financial Performance in Second Quarter FY 17

Revenue of \$215.1 million, up 4.4% versus Q2 FY 16

Revenue growth of +0.9%⁽¹⁾ for Invest for Growth* portfolio lagged consumption growth of 1.5% primarily at top 5 customers

Adjusted EPS of \$0.63⁽²⁾, up 5.0% versus Q2 FY 16

Adjusted Free Cash Flow of \$49.4 million⁽²⁾, up 6.9% versus Q2 FY 16

Total debt paydown of \$100.5 million including proceeds from asset sales

* Invest for Growth portfolio comprised of Core OTC brands and International; reported on a constant currency basis. Core OTC brands reflect: Monistat (after Q2 FY 16), BC/Goody's, Clear Eyes, Dramamine, Debrox, Chloraseptic, Luden's, Little Remedies, Compound W, Nix (after Q2 FY 16), Beano, Efferdent and The Doctor's IRI multi-outlet + C-Store retail dollar sales for relevant period. International includes Canadian consumption for leading retailers, and Australia/ROW shipment data as a proxy for consumption.

Q2 FY 17 Performance Highlights: Continuing to Deliver Against Strategy

Demonstrated Portfolio Growth

- Q2 Revenue of \$215.1 million, up 4.4% versus PY Q2
 - Organic growth of (0.6%)⁽¹⁾ on a constant currency basis as top 5 retailers reduced inventory levels in the quarter
 - Revenue growth of +0.9%⁽¹⁾ for Invest for Growth* portfolio
 - DenTek contributed \$17.2 million of revenue during the quarter, continuing its strong growth
- Q2 consumption growth for Invest for Growth* portfolio of 1.5% outpaced revenue growth
 - Consumption growth in-line with category[†]
- International revenue up 8.9% in Q2 with particular strength in Care Pharma
 - Revenue in Australia up 8.0% in Q2, and up 6.2% in 1H FY 17

Strong Margins and FCF

- Gross Margin of 57.6% in line with Q1 and expectations
- Adjusted EPS of \$0.63⁽²⁾, up 5.0% versus the PY Q2
- Strong Adjusted Free Cash Flow of \$49.4 million⁽²⁾, above the PY Q2 of \$46.2 million
 - Leverage of 4.5x⁽³⁾ compared to 5.0x at the beginning of FY 17

M&A

- Focus on enhancing and executing marketing plans for DenTek
- Successfully completed transition of three brands divested in July from Manage for Cash portfolio
 - Accelerated de-leveraging in first half, building meaningful M&A capacity

* Invest for Growth portfolio is comprised of Core OTC brands and International; reported on a constant currency basis. (See slide 9 for additional details.)
† IRI MULO period ending 10-2-16.

Strong Financial Performance in First Half FY 17

Revenue of \$424.6 million, up 6.6% versus 1H FY 16

Revenue growth of +2.6%⁽¹⁾ for Invest for Growth* portfolio consistent with consumption growth of 2.4%

Adjusted EPS of \$1.22⁽²⁾, up 8.9% versus 1H FY 16


Adjusted Free Cash Flow of \$99.6 million⁽²⁾, up 12.0% versus 1H FY 16

Record debt paydown of \$150.5 million including proceeds from asset sales


* Invest for Growth portfolio is comprised of Core OTC brands and International; reported on a constant currency basis. (See slide 9 for additional details.)

Continued Strong and Consistent Consumption Growth for Invest for Growth Portfolio

Consumption Growth



Organic Revenue Growth⁽¹⁾




Source: Data reflects retail dollar sales percentage growth versus prior period for consumption growth and organic revenue growth. FY 15 and FY 16 data shown as previously presented for Core OTC.

* Q1 and Q2 FY 17 data for Invest for Growth portfolio comprised of Core OTC brands and International. (See slide 9 for additional details.)

Q2 FY 17 Shipments Impacted by U.S. Retailer Inventory Reductions

Top 5 Customers Shipments vs Consumption



Comments

- Shipments to five largest mass and drug accounts have lagged consumption over the last six quarters as retailers continue to manage inventory levels
- In Q2 FY 17 alone, consumption in these accounts outpaced shipments by over \$8.2 million
- Adjusted for this difference, organic revenue growth for Q2 FY 17 on a constant currency basis would have been +3.5%

Source: IRI MULO period ending 10-2-16.

DenTek®: Building The Brand One Year After Acquisition

1	Dental Professional Marketing <ul style="list-style-type: none">■ Secure the Hygienist Recommendation■ Increase Sampling to Drive Trial	
2	Grow The Category <ul style="list-style-type: none">■ New Category and Consumer Insights■ Build Basket with Shopper Insights	
3	Innovate With New Products <ul style="list-style-type: none">■ Pipeline to Deliver Top and Bottom Line Growth■ Consumer Insight Innovation	
4	Expand Domestic And Int'l Distribution <ul style="list-style-type: none">■ Develop Alternate Channels and E-commerce■ Increase Shelf Presence in UK and Germany	
5	Use Digital To Drive Brand Awareness <ul style="list-style-type: none">■ Target High Value Consumers■ Leverage Scale to Drive Efficiencies	

Nix: Brand Building Using Innovation in Product and Marketing to Drive Results

- **Expanding Product Offerings:** New Nix Ultra kills a resistant form of Lice called *“Super Lice”*
- **Innovative Marketing:** Nix partnered with Google and IRI to develop the first ever Lice Tracker. Now consumers and Healthcare Professionals can get **real-time information on lice outbreaks**
- **Digital Consumer Advertising:** The first place consumers go to get information is on line. Nix’s new advertising campaign will **reach consumers with information where and when they need it**
- **Strong Results:** Latest 12 weeks consumption +53% and gained 7.1% ppts. market share

New Products



Innovative Marketing



Digital Advertising



Source: IRI MULO period ending 10-2-16.

III. Financial Overview

Dramamine®

Compound W[®]
WART REMOVER

DenTek®

LUDEN'S®

eat the foods you love!
beano®

LITTLE
REMEDIES®

Efferdent®
ANTI-BACTERIAL DENTURE CLEANSER

Clear
eyes®

BC®

Goody's®

FAST ACTING
Chloraseptic®

Nix®
PERMETHRIN

Hydralyte™

MONISTAT®


Gaviscon
and it's gone®

Debrox®

Care™
Pharmaceuticals

Key Financial Results for Second Quarter Performance

- Solid overall financial performance in the quarter
 - Revenue of \$215.1 million, an increase of 4.4%
 - Adjusted EPS of \$0.63, up 5.0 %
 - Adjusted Free Cash Flow increase of 6.9% to \$49.4 million



Dollar values in millions, except per share data.

FY 17 Second Quarter Consolidated Financial Summary

3 Months Ended

6 Months Ended

Comments

	Q2 FY 17	Q2 FY 16	% Chg	Q2 FY 17	Q2 FY 16	% Chg
Total Revenue	\$ 215.1	\$ 206.1	4.4%	\$ 424.6	\$ 398.2	6.6%
Gross Margin	124.0	119.9	3.4%	245.6	232.2	5.8%
<i>% Margin</i>	57.6%	58.2%		57.8%	58.3%	
A&P	28.6	27.9	2.5%	56.2	54.3	3.5%
<i>% Total Revenue</i>	13.3%	13.5%		13.2%	13.6%	
Adjusted G&A ⁽²⁾	17.3	16.5	4.9%	34.6	32.6	6.0%
<i>% Total Revenue</i>	8.0%	8.0%		8.1%	8.2%	
Adjusted EBITDA⁽²⁾	\$ 78.1	\$ 75.6	3.3%	\$ 154.7	\$ 145.2	6.5%
<i>% Margin</i>	36.3%	36.7%		36.4%	36.5%	
Adjusted Net Income⁽²⁾	\$ 33.8	\$ 31.8	6.2%	\$ 65.2	\$ 59.2	10.1%
Adjusted Earnings Per Share⁽²⁾	\$ 0.63	\$ 0.60	5.0%	\$ 1.22	\$ 1.12	8.9%

- Revenue growth of +4.4%
 - Organic growth of (0.6%) excluding the impact of Fx⁽¹⁾
 - DenTek contributed \$17.2 million of revenue during the quarter
- Gross Margin of 57.6%
- A&P 13.3% of Revenue, \$0.7 million more than Q2 FY 16
- Adjusted EBITDA Margin of 36.3%⁽²⁾
- Adjusted Net Income +6.2%⁽²⁾ over Q2 FY 16, ahead of topline growth

Dollar values in millions, except per share data.

Exceptional Free Cash Flow Trends

Cash Flow

	Three Months Ended		Six Months Ended	
	Q2 FY 17	Q2 FY 16	Q2 FY 17	Q2 FY 16
Net Income - As Reported	\$ 32.2	\$ 31.8	\$ 26.7	\$ 58.0
Depreciation & Amortization	6.0	5.7	12.8	11.4
Other Non-Cash Operating Items*	3.6	14.4	53.5	31.5
Working Capital	7.7	(4.8)	7.2	(10.3)
Operating Cash Flow ⁽⁴⁾	\$ 49.5	\$ 47.1	\$ 100.3	\$ 90.6
Additions to Property and Equipment	(0.5)	(0.9)	(1.4)	(1.7)
Payments Associated with M&A	0.4	-	0.7	-
Adjusted Free Cash Flow ⁽²⁾	\$ 49.4	\$ 46.2	\$ 99.6	\$ 88.9

Comments

- Net Debt at 9/ 30/ 16 of \$1,472 million comprised of:
 - Cash on hand of \$30 million
 - \$752 million of term loan and revolver
 - \$750 million of bonds
- Leverage ratio⁽³⁾ of 4.5x
 - Leverage below prior year level of 5.0 x, including acquisition of DenTek in Q4 FY 16

Dollar values in millions.

* 1H FY 17 increase in Other Non-Cash Operating Items reflects Q1FY 17 after tax loss of approximately \$35 million related to divestitures.

IV. FY 17 Outlook and the Road Ahead

Dramamine®

Compound W[®]
WART REMOVER

DenTek®

LUDEN'S®

eat the foods you love!
beano®

LITTLE
REMEDIES®

Efferdent®
ANTI-BACTERIAL DENTURE CLEANSER

Clear
eyes®

BC®

Goody's®

FAST ACTING
Chloraseptic®

Nix®
PERMETHRIN

Hydralyte™

MONISTAT®

Gaviscon
and it's gone®

Debrox®

Care™
Pharmaceuticals

FY 17 Full Year Outlook – Updated for Impact of Manage for Cash Divestitures

Revenue

Adjusted EPS

Adjusted Free Cash Flow

Updated Outlook to Reflect Sale of Brands

Updated FY Outlook

- Revenue growth of +4% to +6%
 - 1H +5.0 % to +7.0 %
 - 2H +2.5% to +4.5%
 - Organic growth of +1.5% to +2.0 %

- Revenue growth of +4.5% to +6.0 %
 - 1H Actual +6.6%
 - No change
 - Continuing to expect organic growth of 1.5% to 2.0 % in 2H

- Adjusted EPS +6% to +9% (\$2.30 to \$2.36)⁽⁵⁾

- No change

- Adjusted Free Cash Flow of \$185 million⁽⁶⁾ or more

- No change

Q&A

Appendix

- (1) Organic Revenue Growth on a constant currency basis is a Non- GAAP financial measure and is reconciled to its most closely related GAAP financial measure in our earnings release in the “About Non- GAAP Financial Measures” section.
- (2) Adjusted G&A, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted EPS, Adjusted Free Cash Flow are Non- GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and in our earnings release in the “About Non- GAAP Financial Measures” section.
- (3) Leverage ratio reflects net debt / covenant defined EBITDA.
- (4) Operating cash flow is equal to GAAP net cash provided by operating activities.
- (5) Adjusted EPS for FY 17 is a projected Non- GAAP financial measure, is reconciled to projected GAAP EPS in our earnings release in the “About Non- GAAP Financial Measures” section and is calculated based on projected GAAP EPS of \$1.55 to \$1.61 plus \$0 .0 8 of costs associated with DenTek integration plus \$0 .67 of costs associated with the loss on sale of assets, resulting in \$2.30 to \$2.36.
- (6) Adjusted Free Cash Flow for FY 17 is a projected Non- GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in our earnings release in the “About Non- GAAP Financial Measures” section and is calculated based on projected Net Cash Provided by Operating Activities of \$191 million less projected capital expenditures of \$4 million plus payments associated with acquisitions of \$3 million.

Reconciliation Schedules

Organic Revenue Growth

	Three Months Ended Sept. 30 ,		Six Months Ended Sept. 30 ,	
	20 16	20 15	20 16	20 15
<i>(In Thousands)</i>				
GAAP Total Revenues	\$ 215,052	\$ 206,065	\$ 424,627	\$ 398,197
Adjustments:				
DenTek revenues	(17,214)	-	(33,841)	-
Revenues associated with divested brands	-	(6,922)	-	(6,922)
Total adjustments	(17,214)	(6,922)	(33,841)	(6,922)
Non-GAAP Organic Revenues	<u>197,838</u>	<u>199,143</u>	<u>390,786</u>	<u>391,275</u>
Organic Revenue Growth (Decline)	<u>(0.7%)</u>		<u>(0.1%)</u>	
Impact of foreign currency exchange rates		(76)		(905)
Non-GAAP Organic Revenues on a constant currency basis	\$ 197,838	\$ 199,067	\$ 390,786	\$ 390,370
Constant Currency Organic Revenue Growth	<u>(0.6%)</u>		<u>0.1%</u>	

Reconciliation Schedules Cont'd

Adjusted G&A

	Three Months Ended Sept. 30,		Six Months Ended Sept. 30,	
	20 16	20 15	20 16	20 15
<i>(In Thousands)</i>				
GAAP General and Administrative Expense	\$ 18,795	\$ 16,462	\$ 38,252	\$ 34,051
Adjustments:				
Costs Associated with CEO transition	-	-	-	1,406
Legal and professional fees associated with acquisitions and divestitures	101	-	585	-
Integration, transition and other costs associated with acquisitions and divestitures	1,420	-	3,061	-
Total adjustments	1,521	-	3,646	1,406
Non-GAAP Adjusted General and Administrative Expense	\$ 17,274	\$ 16,462	\$ 34,606	\$ 32,645
Non-GAAP Adjusted General and Administrative Expense Percentage	8.0%	8.0%	8.1%	8.2%

Reconciliation Schedules Cont'd

Adjusted EBITDA

	Three Months Ended Sept. 30,		Six Months Ended Sept. 30,	
	20 16	20 15	20 16	20 15
<i>(In Thousands)</i>				
GAAP Net (Loss) Income	\$ 32,195	\$ 31,803	\$ 26,664	\$ 57,976
Interest expense, net	20,830	20,667	41,957	42,551
(Benefit) provision for income taxes	18,033	17,428	14,651	31,425
Depreciation and amortization	6,016	5,687	12,848	11,407
Non-GAAP EBITDA	77,074	75,585	96,120	143,359
Adjustments:				
Costs associated with CEO transitions	-	-	-	1,406
Legal and professional fees associated with acquisitions and divestitures	101	-	585	-
Integration, transition and other costs associated with acquisitions and divestitures	1,420	-	3,061	-
Loss on extinguishment of debt	-	-	-	451
(Gain) loss on sale of assets	(496)	-	54,957	-
Total adjustments	1,025	-	58,603	1,857
Non-GAAP Adjusted EBITDA	\$ 78,099	\$ 75,585	\$ 154,723	\$ 145,216
Non-GAAP Adjusted EBITDA Margin	36.3%	36.7%	36.4%	36.5%

Reconciliation Schedules Cont'd

Adjusted Net Income and Adjusted EPS

	Three Months Ended Sept. 30,				Six Months Ended Sept. 30,			
	20 16		20 15		20 16		20 15	
	Net Income	EPS	Net Income	EPS	Net Income	EPS	Net Income	EPS
<i>(In Thousands)</i>								
GAAP Net Income	\$ 32,195	\$ 0.60	\$ 31,803	\$ 0.60	\$ 26,664	\$ 0.50	\$ 57,976	\$ 1.09
Adjustments:								
Costs associated with CEO transition	-	-	-	-	-	-	1,406	0.03
Legal and professional fees associated with acquisitions and divestitures	101	-	-	-	585	0.01	-	-
Integration, transition and other costs associated with acquisitions and divestitures	1,420	0.03	-	-	3,061	0.06	-	-
Accelerated amortization of debt origination costs due to sale of assets	1,131	0.02	-	-	1,131	0.02	-	-
Loss on extinguishment of debt	-	-	-	-	-	-	451	0.01
(Gain) loss on sale of assets	(496)	(0.01)	-	-	54,957	1.03	-	-
Tax impact of adjustments	(566)	(0.01)	-	-	(21,224)	(0.40)	(657)	(0.01)
Total Adjustments	1,590	0.03	-	-	38,510	0.72	1,200	0.03
Non-GAAP Adjusted Net Income and Adjusted EPS	\$ 33,785	\$ 0.63	\$ 31,803	\$ 0.60	\$ 65,174	\$ 1.22	\$ 59,176	\$ 1.12

Reconciliation Schedules Cont'd

Adjusted Free Cash Flow

	Three Months Ended Sept. 30,		Six Months Ended Sept. 30,	
	20 16	20 15	20 16	20 15
<i>(In Thousands)</i>				
GAAP Net (Loss) Income	\$ 32,195	\$ 31,803	\$ 26,664	\$ 57,976
Adjustments:				
Adjustments to reconcile net (loss) income to net cash provided by operating activities as shown in the Statement of Cash Flows	9,592	20,040	66,388	42,896
Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows	7,744	(4,774)	7,230	(10,282)
Total Adjustments	17,336	15,266	73,618	32,614
GAAP Net cash provided by operating activities	49,531	47,069	100,282	90,590
Purchase of property and equipment	(509)	(903)	(1,404)	(1,683)
Non-GAAP Free Cash Flow	49,022	46,166	98,878	88,907
Integration, transition and other payments associated with acquisitions and divestitures	352	-	683	-
Non-GAAP Adjusted Free Cash Flow	\$ 49,374	\$ 46,166	\$ 99,561	\$ 88,907

Reconciliation Schedules Cont'd

Projected EPS

	20 17 Projected EPS	
	Low	High
Projected FY'17 GAAP EPS	\$ 1.55	\$ 1.61
<u>Adjustments:</u>		
Costs associated with DenTek integration	0.08	0.08
Loss on sale of assets	0.67	0.67
Total Adjustments	0.75	0.75
Projected Non-GAAP Adjusted EPS	\$ 2.30	\$ 2.36

Projected Free Cash Flow

	20 17 Projected Free Cash Flow
<i>(In millions)</i>	
Projected FY'17 GAAP Net Cash provided by operating activities	\$ 191
Additions to property and equipment for cash	(4)
Projected Non-GAAP Free Cash Flow	187
Payments associated with acquisitions	3
Adjusted Non-GAAP Projected Free Cash Flow	190